Do analysts rate ARIX or HVO?

hVIVO has a consensus price target of GBX 15, suggesting a potential upside of 123.81%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better earnings & valuation, ARIX or HVO?

hVIVO has higher revenue and earnings than Arix Bioscience. hVIVO is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arix Bioscience £14.16M 0.00 £14.96M £0.11 N/A hVIVO £46.77M 0.99 £17.84M -£0.87 N/A

Is ARIX or HVO more profitable?

Arix Bioscience has a net margin of 105.64% compared to hVIVO's net margin of -12.48%. Arix Bioscience's return on equity of 6.41% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets Arix Bioscience 105.64% 6.41% 2.18% hVIVO -12.48% -14.65% 11.97%

Which has better earnings and valuation, HVO or BTG?

hVIVO has higher earnings, but lower revenue than BTG. hVIVO is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 0.99 £17.84M -£0.87 N/A BTG £159.40M 1.10 N/A £6.00 18.05

Is HVO or BTG more profitable?

BTG has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. BTG's return on equity of 0.00% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% BTG N/A N/A N/A

Does the media favor HVO or BTG?

In the previous week, BTG had 4 more articles in the media than hVIVO. MarketBeat recorded 5 mentions for BTG and 1 mentions for hVIVO. hVIVO's average media sentiment score of 1.27 beat BTG's score of -0.10 indicating that hVIVO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment hVIVO 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BTG 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate HVO or SCLP?

hVIVO currently has a consensus target price of GBX 15, suggesting a potential upside of 123.81%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts clearly believe hVIVO is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, HVO or SCLP?

hVIVO has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 0.99 £17.84M -£0.87 N/A Scancell £4.71M 29.24 -£6.75M -£0.55 N/A

Is HVO or SCLP more profitable?

hVIVO has a net margin of -12.48% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% Scancell -116.98% 90.29% -45.28%

Does the media refer more to HVO or SCLP?

In the previous week, hVIVO and hVIVO both had 1 articles in the media. hVIVO's average media sentiment score of 1.27 beat Scancell's score of 0.00 indicating that hVIVO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment hVIVO 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scancell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CIR or HVO?

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 123.81%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Circassia Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Circassia Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts recommend HVO or TILS?

hVIVO presently has a consensus price target of GBX 15, suggesting a potential upside of 123.81%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

hVIVO (HVO) Competitors

GBX 6.70 -0.15 (-2.18%)

As of 07:44 AM Eastern

Compare

HVO vs. ARIX, BTG, SCLP, CIR, and TILS

Should you buy hVIVO stock or one of its competitors? MarketBeat compares hVIVO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with hVIVO include Arix Bioscience (ARIX), BTG (BTG), Scancell (SCLP), Circassia Group (CIR), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.

How does hVIVO compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, hVIVO has a beta of 1.707, indicating that its share price is 71% more volatile than the broader market.

hVIVO has higher revenue and earnings than Arix Bioscience. hVIVO is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
hVIVO	£46.77M	0.99	£17.84M	-£0.87	N/A

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 11.8% of hVIVO shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by company insiders. Comparatively, 4.9% of hVIVO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, hVIVO had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Arix Bioscience. hVIVO's average media sentiment score of 1.27 beat Arix Bioscience's score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.

Company	Overall Sentiment
Arix Bioscience	Neutral
hVIVO	Positive

Arix Bioscience has a net margin of 105.64% compared to hVIVO's net margin of -12.48%. Arix Bioscience's return on equity of 6.41% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
hVIVO	-12.48%	-14.65%	11.97%

hVIVO has a consensus price target of GBX 15, suggesting a potential upside of 123.81%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

hVIVO beats Arix Bioscience on 9 of the 15 factors compared between the two stocks.

How does hVIVO compare to BTG?

hVIVO (LON:HVO) and BTG (LON:BTG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

hVIVO has higher earnings, but lower revenue than BTG. hVIVO is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	0.99	£17.84M	-£0.87	N/A
BTG	£159.40M	1.10	N/A	£6.00	18.05

hVIVO pays an annual dividend of GBX 0.20 per share and has a dividend yield of 3.0%. BTG pays an annual dividend of GBX 4.30 per share and has a dividend yield of 4.0%. hVIVO pays out -23.0% of its earnings in the form of a dividend. BTG pays out 71.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

11.8% of hVIVO shares are owned by institutional investors. Comparatively, 19.2% of BTG shares are owned by institutional investors. 4.9% of hVIVO shares are owned by company insiders. Comparatively, 19.7% of BTG shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, BTG had 4 more articles in the media than hVIVO. MarketBeat recorded 5 mentions for BTG and 1 mentions for hVIVO. hVIVO's average media sentiment score of 1.27 beat BTG's score of -0.10 indicating that hVIVO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
hVIVO	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BTG	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

BTG has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. BTG's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
BTG	N/A	N/A	N/A

hVIVO presently has a consensus target price of GBX 15, suggesting a potential upside of 123.81%. BTG has a consensus target price of GBX 160, suggesting a potential upside of 47.71%. Given hVIVO's higher probable upside, research analysts plainly believe hVIVO is more favorable than BTG.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

BTG beats hVIVO on 12 of the 16 factors compared between the two stocks.

How does hVIVO compare to Scancell?

hVIVO (LON:HVO) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, hVIVO and hVIVO both had 1 articles in the media. hVIVO's average media sentiment score of 1.27 beat Scancell's score of 0.00 indicating that hVIVO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
hVIVO	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scancell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

hVIVO has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	0.99	£17.84M	-£0.87	N/A
Scancell	£4.71M	29.24	-£6.75M	-£0.55	N/A

11.8% of hVIVO shares are held by institutional investors. Comparatively, 1.5% of Scancell shares are held by institutional investors. 4.9% of hVIVO shares are held by insiders. Comparatively, 15.5% of Scancell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

hVIVO has a net margin of -12.48% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Scancell	-116.98%	90.29%	-45.28%

hVIVO has a beta of 1.707, suggesting that its share price is 71% more volatile than the broader market. Comparatively, Scancell has a beta of 0.736, suggesting that its share price is 26% less volatile than the broader market.

hVIVO currently has a consensus target price of GBX 15, suggesting a potential upside of 123.81%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts clearly believe hVIVO is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

hVIVO beats Scancell on 11 of the 15 factors compared between the two stocks.

How does hVIVO compare to Circassia Group?

Circassia Group (LON:CIR) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Circassia Group has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Circassia Group's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Circassia Group	N/A	N/A	N/A
hVIVO	-12.48%	-14.65%	11.97%

11.8% of hVIVO shares are held by institutional investors. 4.9% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

hVIVO has higher revenue and earnings than Circassia Group. hVIVO is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A
hVIVO	£46.77M	0.99	£17.84M	-£0.87	N/A

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 123.81%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Circassia Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Circassia Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, hVIVO had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Circassia Group. hVIVO's average media sentiment score of 1.27 beat Circassia Group's score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.

Company	Overall Sentiment
Circassia Group	Neutral
hVIVO	Positive

Summary

hVIVO beats Circassia Group on 9 of the 13 factors compared between the two stocks.

How does hVIVO compare to Tiziana Life Sciences?

hVIVO (LON:HVO) and Tiziana Life Sciences (LON:TILS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Tiziana Life Sciences has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Tiziana Life Sciences' return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Tiziana Life Sciences	N/A	N/A	N/A

hVIVO has higher revenue and earnings than Tiziana Life Sciences. hVIVO is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	0.99	£17.84M	-£0.87	N/A
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A

In the previous week, hVIVO had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Tiziana Life Sciences. hVIVO's average media sentiment score of 1.27 beat Tiziana Life Sciences' score of 0.00 indicating that hVIVO is being referred to more favorably in the media.

Company	Overall Sentiment
hVIVO	Positive
Tiziana Life Sciences	Neutral

hVIVO presently has a consensus price target of GBX 15, suggesting a potential upside of 123.81%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tiziana Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

11.8% of hVIVO shares are held by institutional investors. 4.9% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

hVIVO beats Tiziana Life Sciences on 10 of the 13 factors compared between the two stocks.

Get hVIVO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HVO vs. The Competition

Export

Metric	hVIVO	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£46.14M	£524.40M	£6.96B	£2.78B
Dividend Yield	2.68%	3.90%	2.68%	6.12%
P/E Ratio	-7.70	3.14	27.20	368.15
Price / Sales	0.99	6,506.03	578.26	84,722.19
Price / Cash	4.94	13.13	49.25	27.89
Price / Book	1.21	86.98	10.73	7.49
Net Income	£17.84M	-£96.07M	£3.59B	£5.89B
7 Day Performance	-0.89%	-1.99%	-1.95%	0.03%
1 Month Performance	-15.16%	1.08%	2.19%	-1.36%
1 Year Performance	-35.09%	54.65%	23.80%	62.04%

hVIVO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HVO hVIVO	2.8305 of 5 stars	GBX 6.70 -2.2%	GBX 15 +123.8%	-33.5%	£46.13M	£46.77M	N/A	N/A	Gap Up
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9
BTG BTG	4.37 of 5 stars	GBX 111.15 +0.1%	GBX 160 +43.9%	N/A	£179.11M	£159.40M	18.53	4,690	Gap Down High Trading Volume
SCLP Scancell	N/A	GBX 14 +1.8%	N/A	+37.8%	£145.29M	£4.71M	N/A	51	News Coverage Gap Down
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HVO) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

hVIVO (HVO) Competitors

HVO vs. ARIX, BTG, SCLP, CIR, and TILS

How does hVIVO compare to Arix Bioscience?

Summary

How does hVIVO compare to BTG?

Summary

How does hVIVO compare to Scancell?

Summary

How does hVIVO compare to Circassia Group?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

hVIVO (HVO) Competitors

HVO vs. ARIX, BTG, SCLP, CIR, and TILS

How does hVIVO compare to Arix Bioscience?

Which has more volatility & risk, ARIX or HVO?

Which has better earnings & valuation, ARIX or HVO?

Do institutionals and insiders hold more shares of ARIX or HVO?

Does the media refer more to ARIX or HVO?

Is ARIX or HVO more profitable?

Do analysts rate ARIX or HVO?

Summary

How does hVIVO compare to BTG?

Which has better earnings and valuation, HVO or BTG?

Is HVO or BTG a better dividend stock?

Do institutionals & insiders have more ownership in HVO or BTG?

Does the media favor HVO or BTG?

Is HVO or BTG more profitable?

Do analysts rate HVO or BTG?

Summary

How does hVIVO compare to Scancell?

Does the media refer more to HVO or SCLP?

Which has preferable valuation and earnings, HVO or SCLP?

Do insiders & institutionals hold more shares of HVO or SCLP?

Is HVO or SCLP more profitable?

Which has more risk & volatility, HVO or SCLP?

Do analysts rate HVO or SCLP?

Summary

How does hVIVO compare to Circassia Group?

Is CIR or HVO more profitable?

Do insiders and institutionals hold more shares of CIR or HVO?

Which has higher earnings & valuation, CIR or HVO?

Do analysts recommend CIR or HVO?

Does the media prefer CIR or HVO?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Is HVO or TILS more profitable?

Which has preferable earnings & valuation, HVO or TILS?

Does the media favor HVO or TILS?

Do analysts recommend HVO or TILS?

Do insiders & institutionals have more ownership in HVO or TILS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools